BURLINGTON — ConforMIS Inc. has launched a $1.8 millionoffering of warrants to purchase Series D Preferred Stock or other equity securities.
Last August, the Burlington, Mass.-based company that develops and commercializes medical devices for osteoarthritis treatment and joint damage raised $74.88 million from a $91.2 million offering of Series D Preferred Stock, Convertible Promissory Notes, Series D Warrants, Common Stock Warrants and Common Stock.
Named in the new filing are the following:
– Philipp Lang, CEO, president, chairman
– Judith Huber, CFO
– Ken Fallon, director, former President of Zimmer USA
– Anselm Leung, director, from VIVO Ventures
– Brad Langdale, director
– Frank Muhlenbeck, director
Lang founded ConforMIS in 2004 and has served as Chairman of the Board since its founding. He has been CEO since January 2008. Dr. Lang’s management experience includes positions as the Director of the Musculoskeletal Radiology and Distinguished Weissman Chair at Brigham and Women’s Hospital in Boston and Associate Professor at Harvard Medical School.
ConforMIS’ proprietary intellectual property includes more than 250 patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. ConforMIS knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery.
